Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

Neurologia (Engl Ed). 2019 Jul-Aug;34(6):408-417. doi: 10.1016/j.nrl.2017.09.008. Epub 2017 Nov 21.
[Article in English, Spanish]

Abstract

OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM.

Keywords: Botulinum neurotoxin A; Chronic migraine; Consenso; Consensus; Guidelines; Migraña crónica; OnabotulinumtoxinA; Preventive treatment; Recomendaciones; Toxina botulínica A; Tratamiento preventivo.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / pharmacology*
  • Botulinum Toxins, Type A / therapeutic use*
  • Guidelines as Topic / standards*
  • Humans
  • Migraine Disorders / drug therapy*
  • Neurologists
  • Spain

Substances

  • Botulinum Toxins, Type A
  • onabotulinum toxin A